Scientists at Sanford Burnham Prebys have found in mice that increasing levels of the protein SORLA can reduce toxic tau accumulation, brain shrinkage and damage to the connections between nerve cells. The findings suggest that strengthening the brain’s own protective mechanisms could eventually lead to new treatments for Alzheimer’s disease and other tau-related dementias, although the effects have not yet been demonstrated in humans.
SORLA protects against tau-related brain damage
Tau is essential for healthy brain-cell function. Under normal conditions, the protein stabilizes microtubules, small structures that provide internal support to neurons and help maintain the nervous system’s complex networks.
In Alzheimer’s disease and related conditions, tau can become abnormal and clump together into harmful structures called tau tangles. These tangles disrupt neurons and are associated with cognitive decline and neuronal death. Diseases characterized by abnormal tau accumulation are collectively known as tauopathies.
The researchers studied sorting-associated receptor with type A repeats, or SORLA, a protein already known for its potential role in protecting the brain from Alzheimer’s disease.
Previous studies have shown that SORLA helps limit the production and accumulation of amyloid beta, another protein closely associated with Alzheimer’s disease. Amyloid beta can build up in the brain and form plaques, one of the disease’s main pathological hallmarks alongside tau tangles.
“Over the past 15 to 20 years, considerable data has emerged from our lab and other groups showing that SORLA can suppress the production and accumulation of amyloid beta, which is one of the hallmarks of Alzheimer’s disease,” said Dr. Timothy Huang, assistant professor at the Sanford Burnham Prebys Center for Neurological Diseases.
“However, little was known about whether SORLA affects tau tangles, which is reflected on the other side of the Alzheimer’s disease coin.”
To investigate this question, the scientists bred mice engineered to produce additional human SORLA with mice that develop tau tangles, brain atrophy and cognitive impairment. This model allowed the team to test whether higher SORLA levels could reduce tau accumulation and limit the resulting damage.
Higher SORLA levels reduce toxic tau
The results indicated that additional SORLA protected against several processes involved in the formation of tau tangles and the progression of neurodegenerative disease.
One important process is hyperphosphorylation, which occurs when excessive phosphate groups attach to tau. This changes the protein’s behavior and contributes to the formation of harmful tangles. Higher SORLA levels reduced this abnormal modification.
SORLA also limited the ability of misfolded tau to act as a “seed” that promotes the aggregation of other tau proteins. This seeding process allows toxic tau aggregates to multiply and spread their damaging effects.
In addition, SORLA helped preserve synapses, the specialized connections through which neurons communicate. It also protected synaptic plasticity, the brain’s ability to strengthen or modify those connections, which is essential for learning, memory and normal cognitive function.
“Upregulating SORLA can suppress the negative effects seen in tauopathies,” said Huijie Huang, Ph.D., a staff scientist in the Fan lab at Sanford Burnham Prebys and lead author of the study.
“We found that there was less brain atrophy and tau accumulation, which was a very interesting result.”
Loss of SORLA worsens the damage
After observing the effects of increasing SORLA, the researchers examined what happened when the protein was absent.
SORLA is produced from instructions encoded by the SORL1 gene. Mutations that prevent this gene from functioning can interfere with the production or activity of the protein.
In a separate experiment, the team genetically modified mice so that they could not produce SORLA. The result was the opposite of what the researchers observed in mice carrying additional copies of the protein: the absence of SORLA worsened tau-related damage.
“When we removed the ability to produce SORLA proteins, we found that the opposite was true,” said Tim Huang, senior and corresponding author of the paper. “SORLA deficiency exacerbated the deleterious effects observed in tauopathies.”
Together, the contrasting results provide further evidence that SORLA has a protective role in the brain and may influence the progression of tau-related diseases.
Molecular analysis identifies possible drug targets
To understand why changes in SORLA levels produced such different effects, the researchers examined molecular activity in individual brain cells and surrounding tissues.
They combined advanced sequencing methods that measure protein levels and gene activity in individual cells with techniques that map the locations of RNA and proteins within brain tissue. This approach provided a detailed view of how SORLA affects biological processes involved in neurodegeneration.
The analysis showed that increasing SORLA prevented harmful changes in protein production at synapses and suppressed other mechanisms associated with tauopathy progression.
Higher SORLA levels also reduced abnormal gene activity in glial cells. These cells support, maintain and protect neurons, and changes in their activity may contribute to the progression of neurodegenerative diseases.
One finding pointed to a potential target for existing drugs.
“One particularly remarkable finding that we can make is that members of the plexin B family of receptors are upregulated in the absence of SORLA,” said Huijie Huang.
Plexin B receptors are involved in cell signaling, helping cells respond to information from their surroundings. Their increased activity when SORLA is absent suggests that this signaling pathway may contribute to some of the harmful changes associated with tau disorders.
Drugs that target this receptor family already exist, raising the possibility that researchers could investigate whether they might be useful against tau-related dementia.
“We have unique drugs that can target this class of receptors and may have applications in tau-related dementia diseases,” said Tim Huang. “One possible future direction is to repurpose these drugs to target glial cell hyperactivation and perhaps reverse some of the tauopathy phenotypes.”
Next steps in human research
Although the findings are encouraging, the protective effects have so far been demonstrated only in mice. Further research is needed to determine whether the same mechanisms operate in humans.
The research team plans to investigate how different types of brain cells respond when SORLA levels increase or decrease. One possible approach would involve transplanting human neurons or glial cells into mouse brains, allowing researchers to examine the effects of different SORLA mutations in living, disease-affected tissue.
“Mouse cells and human cells are different,” said Tim Huang. “Since we are looking at human disease, it will be more informative if we can observe SORLA modulation and dysfunction in the context of human cells within the diseased brain environment.”
These experiments could help clarify how SORLA protects neurons from toxic tau accumulation and why disruption of its function worsens neurodegeneration.
Ultimately, the researchers hope that a better understanding of SORLA will reveal new therapeutic strategies, either by increasing the protein’s activity or by repurposing existing drugs to inhibit damaging cellular pathways. Such approaches could eventually offer new ways to address Alzheimer’s disease and other dementias associated with toxic tau tangles.
This research was supported by the National Institutes of Health, the National Cancer Institute and the National Institute on Aging.
Source: www.sciencedaily.com


